Oligonucleotides for CNS Summit Europe

Memo

Europe's oligonucleotide landscape is entering a pivotal growth phase. With the €21M launch of Aerska and major collaborations such as Novartis and SciNeuron, Lundbeck and Contera, and Secarna and Vect-Horus, European biopharma are rapidly advancing RNA-targeted approaches to address previously undruggable CNS diseases. In response to this momentum, the inaugural Oligonucleotides for CNS Summit Europe will unite 60+ senior industry leaders for the first European forum dedicated exclusively to CNS-focused Oligonucleotide therapeutics. The summit delivers three days of highly technical, data-driven discussions addressing the challenges unique to CNS development with insight into next-generation BBB delivery strategies beyond TfR1, advanced in vivo and iPSC models, novel chemistry and conjugation approaches, and translational strategies bridging preclinical data to clinical and regulatory success. Now is the moment to connect, collaborate, and shape the next wave of RNA-based CNS innovation as the field accelerates globally.URLs:Tickets: https://go.evvnt.com/3448230-2?pid=5569Brochure: https://go.evvnt.com/3448230-3?pid=5569Date and Time: On Tuesday April 21, 2026 at 8:00 am to Thursday April 23, 2026 at 4:00 pmVenue details: Novotel Amsterdam Schiphol Airport, 12 Taurusavenue, Hoofddorp, Noord-Holland, 2132 LS, NetherlandsPrices:Conference + Pre-Conference Workshop Day + Breakfast Briefing - Drug Developer: EUR 3946.00,Conference + Pre-Conference Workshop Day - Drug Developer: EUR 3397.00,Conference Only - Drug Developer: EUR 2499.00,Conference + Pre-Conference Workshop Day + Breakfast Briefing - Academic: EUR 3246.00,Conference + Pre-Conference Workshop Day - Academic: EUR 2797.00,Conference Only - Academic: EUR 2099.00,Conference + Pre-Conference Workshop Day - Solution Provider: EUR 4797.00,Conference Only - Solution Provider: EUR 3499.00Speakers: Farzaneh Salem, Associate Director, PB/ PK Modelling, GSK, Michal Lubas, Novel Technologies and Therapeutics Lead, Lundbeck, Felix Schumacher, Mission Lead RNAHub, Roche, Helene Tran, Director, Head of Antisense Oligonucleotide Therapeutic Program, Servier, Duygu Yilmaz, Director RNA Therapeutics and Translational Science, Aerska, Macarena Hernandez, Chief Scientific Officer, AptaTargets, Beatriz Llamusi Troisi, Chief Scientific Officer and Co-Founder, Arthex Biotech, Chris Shaw, Chief Scientific and Clinical Advisor, CoFounder, AviadoBio, Soren Rasmussen, Chief Scientific Officer, Contera Pharma, Guillaumje Hautbergue, Chief Scientific Officer, Crucible Therapeutics, Jan Thirkettle, Chief Executive Officer,Harness Therapeutics, Gerard Platenburg, Chief Scientific Officer and Co-Founder, ProQR Therapeutics, Miriam Bujny, Chief Development Officer, Sapreme Technologies, Irene Tur, Senior Scientist, Secarna Pharmaceuticals, Piotr Putaj, Director, Oligonucleotide Chemistry, Vico Therapeutics, Poul Sorensen, Chief Executive Officer, Inverna Therapeutics